Recent health assessments of President Trump indicate he is in “good health,” citing his numerous golf victories as a point of reference.
However, a new study published in Jama Network Open raises some concerns. His enthusiasm for golf at Mar-a-Lago could expose him to a higher risk for an unexpected health issue.
According to the study, which analyzed data from over 5,500 individuals, living within one mile of a golf course increased the risk of developing Parkinson’s disease by 126% compared to those residing more than six miles away. Even at a distance of three miles, the risk remains elevated.
Researchers suggest that this increased risk may be linked to exposure to pesticides that are commonly used on golf courses.
These chemicals can seep into groundwater or become airborne, potentially affecting nearby residents.
The risk for people relying on groundwater for drinking was notably higher, especially in areas vulnerable to contamination.
Mar-a-Lago, where Trump lives and works, includes golf courses and is situated in a region with high groundwater levels, possibly heightening the risk of water pollution.
It’s worth mentioning that while the study indicates a potential link between living near golf courses and a higher likelihood of Parkinson’s disease, it does not establish a direct cause-and-effect relationship. These conclusions align with findings from previous research regarding pesticides.
According to researchers Catherine Fletcher and her colleagues, “Many studies are investigating whether pesticides increase the risk of developing Parkinson’s disease in diverse populations globally.” They also noted, “While the findings differ, they generally suggest that pesticide exposure may elevate the risk, but it’s not definitive enough to prove it causes Parkinson’s.”
Approximately 1.1 million people in the U.S. are currently diagnosed with Parkinson’s disease.
Currently, there are no cures for these neurodegenerative disorders, but treatment options are improving.
Recent studies have indicated that psychedelic compounds, like those found in “magic mushrooms,” could significantly enhance mood and motor functions in individuals with Parkinson’s.
A new drug, Tavapadon, has shown promise in clinical trials by mimicking dopamine and targeting specific brain receptors, thus reducing variability in symptoms while causing fewer side effects compared to traditional treatments.
Additionally, Prodaudopa, the UK’s first continuous infusion therapy for this condition, received FDA approval in the previous fall.
Experts advise that maintaining a healthy diet could help decrease the risk of developing Parkinson’s disease, which might mean cutting back on fast food — at least for now.
